Isan Chen, MBrace Therapeutics president and CEO
November 14, 2023 08:30 AM ESTUpdated 12:42 PM
Financing
Startups

MBrace Ther­a­peu­tics cap­i­tal­izes on ADC wave with $85M Se­ries B to en­ter the clin­ic this quar­ter

Kyle LaHucik

Senior Reporter

MBrace Ther­a­peu­tics has raised an $85 mil­lion Se­ries B for a Phase I clin­i­cal tri­al of its first an­ti­body-drug con­ju­gate as in­vestors and Big Phar­mas …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times